MapLight's schizophrenia drug dampens once‑daily hopes despite Phase 2 win

MapLight Therapeutics' schizophrenia drug ML-007C-MA, an oral M1/M4 muscarinic agonist combination of betovumeline and fesoterodine, met its primary endpoint in the Phase 2 ZEPHYR trial with a statistically significant improvement in PANSS total score at Week 5 for the 210/3 mg twice-daily (BID) dose versus placebo, with a mean 4.5-point improvement and effect size of 0.37 (p=0.015).

The once-daily 330/6 mg dose did not achieve statistical significance on the primary PANSS endpoint, missing the hoped-for once‑daily advantage, though it showed numerical benefit and significant separation on some secondary endpoints like CGI-S and PANSS positive Marder factor.

ML-007C-MA was generally well tolerated with mostly mild, cholinergic‑type adverse events, no serious or drug‑related severe adverse events, and low all‑cause discontinuation (19.9%); the BID arm also showed a robust and clinically meaningful improvement in cognitive performance independent of symptom reduction.

Analysts view the BID results as a clinically meaningful win but not a game‑changer versus the approved rival muscarinic agonist Cobenfy, which delivered larger PANSS reductions in Phase 3; the failed once‑daily arm has dampened enthusiasm and led to a sharp drop in MapLight’s share price (down about 55–73% on the day of the readout).

MapLight plans an End‑of‑Phase 2 meeting with the FDA and anticipates a confirmatory Phase 3 trial focused on the successful BID regimen, while continuing to explore an optimized once‑daily formulation in schizophrenia and expanding into Alzheimer’s disease psychosis.